Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $2.9 billion.

  • BridgeBio Pharma's Total Non-Current Liabilities rose 55.09% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 55.09%. This contributed to the annual value of $2.4 billion for FY2024, which is 26.20% up from last year.
  • BridgeBio Pharma's Total Non-Current Liabilities amounted to $2.9 billion in Q3 2025, which was up 2.18% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Total Non-Current Liabilities registered a high of $2.9 billion during Q3 2025, and its lowest value of $1.5 billion during Q1 2021.
  • For the 3-year period, BridgeBio Pharma's Total Non-Current Liabilities averaged around $2.2 billion, with its median value being $1.9 billion (2023).
  • In the last 5 years, BridgeBio Pharma's Total Non-Current Liabilities skyrocketed by 216.68% in 2021 and then fell by 0.81% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Total Non-Current Liabilities (Quarterly) stood at $1.9 billion in 2021, then declined by 0.81% to $1.8 billion in 2022, then increased by 2.28% to $1.9 billion in 2023, then climbed by 26.20% to $2.4 billion in 2024, then skyrocketed by 55.09% to $2.9 billion in 2025.
  • Its Total Non-Current Liabilities was $2.9 billion in Q3 2025, compared to $2.9 billion in Q2 2025 and $2.5 billion in Q1 2025.